Journal
AMERICAN JOURNAL OF NEURORADIOLOGY
Volume 31, Issue 2, Pages 235-236Publisher
AMER SOC NEURORADIOLOGY
DOI: 10.3174/ajnr.A1987
Keywords
-
Ask authors/readers for more resources
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available